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Background
HIV and Tuberculosis show high co-prevalence and
cause high morbidity and mortality, especially in infants.
There is no HIV vaccine, and the only licensed TB vac-
cine, BCG, can cause disseminated disease in HIV-
infected infants. We propose to develop a pediatric com-
bination HIV-TB vaccine hypothesizing that a highly
attenuated strain of M. tuberculosis (AMtb) (i) would
result in improved safety, but similar immunogenicity
compared to BCG, (ii) could be modified to co-express
HIV genes (rAMtb-HIV), and (iii) therefore induce HIV
and Mtb specific immunity. Towards this goal, we tested
distinct H37Rv Mtb mutants that differed in their
attenuation for replication and immune evasion in infant
rhesus macaques.
Methods
Six infants that were SIV infected at birth, and 20 healthy
infants received rAMtb-SIV orally at one week of age, and
were followed for 3-6 months. Vaccine safety was assessed
by clinical monitoring, histopathology, and Mtb detection
using multiple culture methods. SIV and Mtb-specific
T cell responses were measured by flow cytometry.
Plasma, saliva and stool were tested for SIV and Mtb anti-
body responses.
Results
Among three vaccine tested, the rAMtb-SIV strain
mc6435 with deletions in panCD, LeuCD, and secA2
was determined to be safe in healthy and SIV-infected
infant macaques. Lungs and other tissues were free of
TB pathology, and viable mycobacilli could not be
recovered from any tissues despite severe immune sup-
pression by SIV.
Immunized animals showed increased dendritic cell
activation, elicited polyfunctional SIV- and TB-specific
CD4+ and CD8+ T cell responses in blood and tissues,
and developed plasma IgG antibodies specific for Mtb
and for SIV. The effectiveness of oral immunization was
confirmed by detection of mucosal IgA responses to SIV
in saliva and stool.
Conclusion
A rAMtb-SIV vaccine is a safe alternative to BCG, is
immunogenic in infants, and could be developed as a
combination vaccine against pediatric HIV and Mtb
infections.
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